Du är här


Moberg Pharma: Redeye: Challenging for Moberg Pharma to reach positive net earnings for the full year

Moberg Pharma's revenue in 2Q'17 was in line with our expectations,
but higher OPEX resulted in EBITDA lower than our expectations and
the consensus.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.